Liquidia Receives FDA's Fast Track Designation For YUTREPIA Inhalation Powder To Treat Raynaud's Phenomenon Associated With Systemic Sclerosis
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that the U.S. Food
Liquidia's medicine for a rare vascular disease got special FDA permission to move faster through approval. This means the company's drug is on a speedier path, which could help patients sooner and shows the FDA thinks the medicine might be really useful.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.